Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Crizotinib - Pfizer

Next Previous
Search
Drug Profile

Crizotinib - Pfizer

Alternative Names: PF-002341066; PF-02341066; PF-1066; PF-2341066; Xalkori

Latest Information Update: 14 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Astellas Pharma; Children's Oncology Group; Dana-Farber Cancer Institute; National Cancer Institute (USA); OxOnc Development; Pfizer; University of Colorado at Denver; University of Milan Bicocca
  • Class Antineoplastics; Chlorobenzenes; Fluorobenzenes; Piperidines; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; Proto-oncogene protein c-met inhibitors; ROS1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma; Non-small cell lung cancer; Non-Hodgkin's lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaplastic large cell lymphoma; Non-small cell lung cancer
  • Phase II Bladder cancer; Non-Hodgkin's lymphoma; Renal cell carcinoma
  • Phase I/II Neuroblastoma; Solid tumours
  • No development reported Cancer; Glioblastoma; Prostate cancer

Most Recent Events

  • 04 Mar 2024 Expanded access program is no longer available for Non-small cell lung cancer (In Children, In adults, In the elderly, Metastatic disease) in USA (PO) (NCT02473497)
  • 09 Nov 2023 Pfizer terminates phase I trial in Malignant neoplasms in the US, China, Italy, Japan, South Korea, Russia and Taiwan due to availability of commercial supply or a rollover study that will allow active subjects to continue receiving treatment (NCT01121588; EudraCT-2010-022978-14)
  • 19 Oct 2023 National Cancer Institute complates a phase II trial for Renal cell carcinoma (Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in the USA and Canada (PO) (NCT02761057)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top